Iloprost Ratiopharm

Iloprost, the active ingredient in Iloprost Ratiopharm, is a prostacyclin analog presented as a intravenous solution for intravenous use. It treats pulmonary arterial hypertension and digital ulcers associated with systemic sclerosis in adult patients.

GNH USA supplies Iloprost Ratiopharm as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Iloprost acts on the prostacyclin pathway to manage severe vascular conditions.

Pulmonary arterial hypertension: reduces pulmonary arterial pressure and improves functional capacity. Digital ulcers associated with systemic sclerosis: promotes ulcer healing and reduces pain.

Iloprost may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Jaw pain: discomfort during chewing. - Nausea or vomiting: gastrointestinal upset. - Diarrhea: loose stools. - Hypotension: temporary drop in blood pressure.

Serious or Rare Side Effects: - Severe hypotension: may require medical intervention. - Pulmonary edema: accumulation of fluid in the lungs. - Bleeding complications: especially when combined with anticoagulants. - Thrombocytopenia: reduced platelet count. - Chest pain or myocardial ischemia: rare cardiac events.

Iloprost requires careful monitoring and specific handling precautions.

Monitor blood pressure: watch for symptomatic hypotension. Assess bleeding risk: avoid in patients with active hemorrhage. Use caution in pulmonary edema: discontinue if fluid overload occurs. Avoid in severe coronary artery disease: risk of myocardial ischemia. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iloprost can interact with several drug classes.

Major Interactions (Avoid): - Concomitant potent vasodilators (e.g., nitroglycerin): may cause severe hypotension. - Anticoagulants (e.g., warfarin, heparin): increased risk of bleeding.

Moderate Interactions (Monitor Closely): - NSAIDs: may diminish antiplatelet effect. - Calcium channel blockers: additive vasodilatory response. - Other prostacyclin analogs (e.g., epoprostenol): potential for excessive pulmonary vasodilation.